OCT 12, 2017 6:00 AM PDT

Disparities in Colorectal Cancer

Speaker
  • John G Searle Professor of Internal Medicine, Professor and Chair Department of Internal Medicine, Professor of Human Genetics, UMHS Internal Medicine, University of Michigan

Abstract

Colorectal cancer (CRC) is the third most common cancer among Americans, and the second deadliest. Its pathogenesis results from an interplay between environmental factors that influence biological behavior of colonic stem cells, and the genetic makeup of susceptible individuals. Activation of stem cell proliferation from this interplay eventually yields adenomatous polyps, which if not removed after detection through an effective screening program, may further progress to cancers that may metastasize and affect survival. This normal-to-polyp-to-cancer process appears to occur at different initiation ages and progresses at different rates among various races in the United States, with African Americans demonstrating the highest incidence and mortality for CRC among all races. Compared with Caucasians, African American CRC patients tend to present at a younger age, have a more proximal cancer, present with more advanced stage, and show shortened survival. In parallel, African Americans demonstrate higher risk adenomatous polyps and more proximally-located polyps than Caucasians as the precursor lesions to CRC. There are likely multifactorial factors that contribute to this disparity, including socio-economic, health insurance, and educational factors, CRC screening utilization, diet, obesity, and microbiome makeup of the colon, tobacco utilization, use of NSAIDs and hormone replacement therapy, and differences in biology of the tumor and/or metastasis. Increasing CRC screening rates towards 80% utilization or greater for African Americans suggests that this disparity may be lessened or disappear. Other strategies such as enhanced patient and physician education and patient navigation for colonoscopy may also reduce the disparity. The U.S. Multi-Society Task Force on Colorectal Cancer, for the first time as of July 2017, endorsed lowering the screening age for African Americans from 50 years of age to 45 years of age, an age where the proportion of CRCs below age 45 years matches the proportion of CRCs among Caucasians below 50 years of age. Employment of these and other strategies may further mitigate the observed disparities.


Show Resources
You May Also Like
DEC 02, 2020 8:00 AM PST
C.E. CREDITS
DEC 02, 2020 8:00 AM PST
DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
OCT 08, 2020 7:00 AM PDT
C.E. CREDITS
OCT 08, 2020 7:00 AM PDT
DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
SEP 10, 2020 9:00 AM PDT
C.E. CREDITS
SEP 10, 2020 9:00 AM PDT
Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
NOV 16, 2020 8:00 AM PST
C.E. CREDITS
NOV 16, 2020 8:00 AM PST
Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
NOV 18, 2020 8:00 AM PST
C.E. CREDITS
NOV 18, 2020 8:00 AM PST
DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
AUG 25, 2020 8:00 AM PDT
C.E. CREDITS
AUG 25, 2020 8:00 AM PDT
DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
Loading Comments...
Show Resources
Attendees
  • See more